HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico

Salud Publica Mex. 2016 Apr;58(2):211-9. doi: 10.21149/spm.v58i2.7790.


Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals.

Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary.

Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combining HPV vaccination and hrHPV-based screening to safety extend screening intervals.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Clinical Trials as Topic / methods*
  • Early Detection of Cancer*
  • Female
  • Human papillomavirus 11 / immunology
  • Human papillomavirus 16 / immunology
  • Human papillomavirus 18 / immunology
  • Human papillomavirus 6 / immunology
  • Humans
  • Mexico
  • Middle Aged
  • Papillomavirus Vaccines*
  • Population Surveillance
  • Preventive Health Services / organization & administration*
  • Program Evaluation
  • Research Design
  • Uterine Cervical Dysplasia / diagnosis
  • Uterine Cervical Dysplasia / epidemiology
  • Uterine Cervical Dysplasia / virology
  • Uterine Cervical Neoplasms / diagnosis
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology
  • Vaccination*


  • Papillomavirus Vaccines